Magcath, a Copenhagen-based medical device company, has received an additional €535,000 (4 million Danish kroner) from its 36 existing Danish and Swiss business angel investors to support the upcoming European launch of its female incontinence treatment device. This follows a €737,000 (5.5 million kroner) investment from the same investor group in July 2024.
The company expects to receive CE mark approval for Obtinu, its silicone urethral device with a magnetic valve for controlling urination, by July 2025. The product allows women to wear it throughout the day without requiring replacement.
“There is no product on the market that is identical to Obtinu. Obtinu’s magnetic opening and closing valve, which makes it possible to wear it all day and still urinate as needed, is unique,” Camilla Harder Hartvig, recently appointed chairperson, told MedWatch.
Incontinence affects 25-45% of women at some point in their lives and approximately 128 million women globally. The company will initially launch in Denmark before expanding to other European markets.
Founded in 2013, Magcath has secured approximately €2.8 million (21 million kroner) in total funding. Previous investors include Seed Capital, Innovation Fund Denmark, and the Market Development Fund. The company’s original 2018 launch target was delayed due to needed improvements in user-friendliness and the transition from MDD to MDR regulations in Europe.
